Health Brief: AMA Billing-Code Suit, HHS Gender-Care Probe and New Alzheimer's Tracer

Health Brief: Legal Fights, Outbreak Updates and an FDA Approval

This week's health news is dominated by legal and regulatory friction over medical billing. A healthcare advocacy group has sued the American Medical Association seeking transparency around the CPT billing codes that form the common language of U.S. medical reimbursement. At the same time, the Department of Health and Human Services accused dozens of hospitals and healthcare providers of improper billing for gender-affirming care in minors and asked the Justice Department to investigate.

Vaccine and voting disputes are also in motion. Sen. Bill Cassidy said he is confident the new CDC director will not enforce President Trump's executive order calling for major changes to the childhood vaccine schedule, while a group of senators charged that CMS guidance changes are designed to disenfranchise nursing home residents from voting. Sen. Elizabeth Warren separately asked HHS Secretary Robert F. Kennedy Jr. whether the cyclosporiasis outbreak response was influenced by Taylor Farms donations to Trump-linked groups. Years of data also show COVID vaccination is safe during pregnancy, according to The New York Times.

On the clinical and public-health front, Congo's Ebola outbreak has reached a sixth province, and Merck's Ervebo vaccine is expected to enter clinical trials there; investigational vaccines targeting the Bundibugyo virus causing the outbreak would follow. In the U.S., a North Carolina study reported that Lyme-carrying ticks are migrating farther south, and the FDA approved Lantheus Holdings' Tauklarify (florquinitau F18) to help identify tau pathology during PET scans for patients being evaluated for Alzheimer's disease.

Other briefs include a $4 million HHS initiative to expand rapid prenatal syphilis testing, a recall of about 213,500 Goody King magnetic toys after ingestion injuries led to at least two child surgeries, a securities fraud lawsuit against Selena Gomez over the mental health startup Wondermind, reports of a mental health crisis aboard the USS Abraham Lincoln, and the death of Chintan Shah, MD, a University of Florida assistant professor who was facing child pornography charges.

Where the Pressure Points Are: Billing Codes, Gender-Care Claims and Vaccine Choice

The AMA's CPT code system is now a legal battleground

CPT codes underpin nearly every U.S. medical bill, and the AMA maintains and licenses them. The transparency lawsuit is significant because a ruling or settlement that changes code access could force insurers, billing vendors and physician practices to alter reimbursement workflows. The case is early, but it puts the AMA's control of a critical billing standard under formal legal scrutiny.

HHS gender-care billing review moves toward enforcement

HHS has not simply criticized the billing practices; it has asked the Justice Department to investigate dozens of hospitals and other providers. That shifts the dispute from a policy argument into potential legal exposure. The allegations are not proven, and the distinction between a clinical disagreement and fraudulent billing will matter. For providers, the immediate cost is administrative and legal uncertainty.

Vaccine and CMS voting disputes are claims, not findings

Sen. Cassidy's statement is a political signal about how the CDC director may handle the vaccine-schedule executive order, but it does not change current policy. The senators' charge that CMS guidance disenfranchises nursing home residents is an allegation, not an established fact. The Warren letter on Taylor Farms also asks a question rather than asserting a proven link. These stories carry reputational weight, but they need further evidence to become policy conclusions.

Congo's outbreak exposes a vaccine strain mismatch

Ervebo is specific to the Zaire ebolavirus, while the current outbreak is being driven by the Bundibugyo virus. That mismatch makes the investigational Bundibugyo-specific vaccines the more direct tool. The plan to begin Ervebo trials first and follow with strain-specific candidates reflects the practical difficulty of deploying licensed vaccines against a different viral strain in an active outbreak.

Tauklarify is a diagnostic advance, not a treatment

The FDA approval gives clinicians a new way to detect tau neurofibrillary tangle pathology in patients with cognitive impairment being evaluated for Alzheimer's. It improves diagnostic information and gives Lantheus Holdings a commercial foothold in Alzheimer's imaging, but it does not slow or treat the disease.

What Health Leaders and Patients Should Watch Next

• Hospitals and clinicians should review documentation and billing for gender-affirming care in minors now, because HHS has already asked the Justice Department to investigate dozens of providers.
• Insurers, billing vendors and physician practices that rely on CPT codes should track the AMA transparency lawsuit; a change in code access or licensing would directly affect reimbursement workflows.
• Neurology and imaging centers evaluating Alzheimer's patients can assess Tauklarify's role alongside existing PET markers, while recognizing it is a diagnostic tool, not a disease-modifying therapy.
• State and local public health agencies in the southeastern U.S. should update Lyme disease surveillance after the North Carolina study showing southward tick migration.
• Global health responders in Congo should prepare for Bundibugyo-specific vaccine trial logistics, because Ervebo targets the Zaire ebolavirus rather than the virus driving the current outbreak.
• Parents and retailers should remove recalled Goody King magnetic building toys from use; the ingestion hazard has already led to at least two child surgeries.